Posted at 22:27h
in News to Know
Another entry in the race to develop a new generation of migraine treatments is showing promise. Lasmiditan (also known as COL-144) was found to be effective for acute migraine attacks in a Phase IIb study. CoLucid Pharmaceuticals, Inc. describes the drug as "a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5HT1F receptors expressed in the trigeminal nerve pathway."